227 related articles for article (PubMed ID: 33495604)
1. Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma.
Jerby-Arnon L; Neftel C; Shore ME; Weisman HR; Mathewson ND; McBride MJ; Haas B; Izar B; Volorio A; Boulay G; Cironi L; Richman AR; Broye LC; Gurski JM; Luo CC; Mylvaganam R; Nguyen L; Mei S; Melms JC; Georgescu C; Cohen O; Buendia-Buendia JE; Segerstolpe A; Sud M; Cuoco MS; Labes D; Gritsch S; Zollinger DR; Ortogero N; Beechem JM; Petur Nielsen G; Chebib I; Nguyen-Ngoc T; Montemurro M; Cote GM; Choy E; Letovanec I; Cherix S; Wagle N; Sorger PK; Haynes AB; Mullen JT; Stamenkovic I; Rivera MN; Kadoch C; Wucherpfennig KW; Rozenblatt-Rosen O; Suvà ML; Riggi N; Regev A
Nat Med; 2021 Feb; 27(2):289-300. PubMed ID: 33495604
[TBL] [Abstract][Full Text] [Related]
2. Truncated SSX protein suppresses synovial sarcoma cell proliferation by inhibiting the localization of SS18-SSX fusion protein.
Yoneda Y; Ito S; Kunisada T; Morimoto Y; Kanzaki H; Yoshida A; Shimizu K; Ozaki T; Ouchida M
PLoS One; 2013; 8(10):e77564. PubMed ID: 24130893
[TBL] [Abstract][Full Text] [Related]
3. SS18-SSX, the Oncogenic Fusion Protein in Synovial Sarcoma, Is a Cellular Context-Dependent Epigenetic Modifier.
Tamaki S; Fukuta M; Sekiguchi K; Jin Y; Nagata S; Hayakawa K; Hineno S; Okamoto T; Watanabe M; Woltjen K; Ikeya M; Kato T; Toguchida J
PLoS One; 2015; 10(11):e0142991. PubMed ID: 26571495
[TBL] [Abstract][Full Text] [Related]
4. SS18-SSX drives CREB activation in synovial sarcoma.
Cyra M; Schulte M; Berthold R; Heinst L; Jansen EP; Grünewald I; Elges S; Larsson O; Schliemann C; Steinestel K; Hafner S; Simmet T; Wardelmann E; Kailayangiri S; Rossig C; Isfort I; Trautmann M; Hartmann W
Cell Oncol (Dordr); 2022 Jun; 45(3):399-413. PubMed ID: 35556229
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.
Lubieniecka JM; de Bruijn DR; Su L; van Dijk AH; Subramanian S; van de Rijn M; Poulin N; van Kessel AG; Nielsen TO
Cancer Res; 2008 Jun; 68(11):4303-10. PubMed ID: 18519690
[TBL] [Abstract][Full Text] [Related]
6. Synovial Sarcoma Oncogenesis Revealed by Single-Cell Profiling.
Qiu A; Nielsen TO
Trends Cancer; 2021 Jun; 7(6):482-483. PubMed ID: 33893065
[TBL] [Abstract][Full Text] [Related]
7. SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma.
Isfort I; Cyra M; Elges S; Kailayangiri S; Altvater B; Rossig C; Steinestel K; Grünewald I; Huss S; Eßeling E; Mikesch JH; Hafner S; Simmet T; Wozniak A; Schöffski P; Larsson O; Wardelmann E; Trautmann M; Hartmann W
Clin Cancer Res; 2019 Jun; 25(12):3718-3731. PubMed ID: 30814111
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial strategies to potentiate the efficacy of HDAC inhibitors in fusion-positive sarcomas.
Lanzi C; Cassinelli G
Biochem Pharmacol; 2022 Apr; 198():114944. PubMed ID: 35152144
[TBL] [Abstract][Full Text] [Related]
9. Synovial sarcoma is a gateway to the role of chromatin remodeling in cancer.
Zöllner SK; Rössig C; Toretsky JA
Cancer Metastasis Rev; 2015 Sep; 34(3):417-28. PubMed ID: 26277104
[TBL] [Abstract][Full Text] [Related]
10. SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.
Trautmann M; Sievers E; Aretz S; Kindler D; Michels S; Friedrichs N; Renner M; Kirfel J; Steiner S; Huss S; Koch A; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Waha A; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
Oncogene; 2014 Oct; 33(42):5006-16. PubMed ID: 24166495
[TBL] [Abstract][Full Text] [Related]
11. Identification of cytotoxic agents disrupting synovial sarcoma oncoprotein interactions by proximity ligation assay.
Laporte AN; Ji JX; Ma L; Nielsen TO; Brodin BA
Oncotarget; 2016 Jun; 7(23):34384-94. PubMed ID: 27120803
[TBL] [Abstract][Full Text] [Related]
12. The impact of chromosomal translocation locus and fusion oncogene coding sequence in synovial sarcomagenesis.
Jones KB; Barrott JJ; Xie M; Haldar M; Jin H; Zhu JF; Monument MJ; Mosbruger TL; Langer EM; Randall RL; Wilson RK; Cairns BR; Ding L; Capecchi MR
Oncogene; 2016 Sep; 35(38):5021-32. PubMed ID: 26947017
[TBL] [Abstract][Full Text] [Related]
13. Synovial Sarcoma: A Complex Disease with Multifaceted Signaling and Epigenetic Landscapes.
El Beaino M; Rassy E; Hadid B; Araujo DM; Pavlidis N; Lin PP
Curr Oncol Rep; 2020 Oct; 22(12):124. PubMed ID: 33025259
[TBL] [Abstract][Full Text] [Related]
14. SYT-SSX is critical for cyclin D1 expression in synovial sarcoma cells: a gain of function of the t(X;18)(p11.2;q11.2) translocation.
Xie Y; Skytting B; Nilsson G; Gasbarri A; Haslam K; Bartolazzi A; Brodin B; Mandahl N; Larsson O
Cancer Res; 2002 Jul; 62(13):3861-7. PubMed ID: 12097301
[TBL] [Abstract][Full Text] [Related]
15. A Novel SS18-SSX Fusion-specific Antibody for the Diagnosis of Synovial Sarcoma.
Baranov E; McBride MJ; Bellizzi AM; Ligon AH; Fletcher CDM; Kadoch C; Hornick JL
Am J Surg Pathol; 2020 Jul; 44(7):922-933. PubMed ID: 32141887
[TBL] [Abstract][Full Text] [Related]
16. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics.
Su L; Sampaio AV; Jones KB; Pacheco M; Goytain A; Lin S; Poulin N; Yi L; Rossi FM; Kast J; Capecchi MR; Underhill TM; Nielsen TO
Cancer Cell; 2012 Mar; 21(3):333-47. PubMed ID: 22439931
[TBL] [Abstract][Full Text] [Related]
17. Deflection of vascular endothelial growth factor action by SS18-SSX and composite vascular endothelial growth factor- and chemokine (C-X-C motif) receptor 4-targeted therapy in synovial sarcoma.
Wakamatsu T; Naka N; Sasagawa S; Tanaka T; Takenaka S; Araki N; Ueda T; Nishizawa Y; Yoshikawa H; Itoh K
Cancer Sci; 2014 Sep; 105(9):1124-34. PubMed ID: 24975049
[TBL] [Abstract][Full Text] [Related]
18. The fusion protein SS18-SSX1 employs core Wnt pathway transcription factors to induce a partial Wnt signature in synovial sarcoma.
Cironi L; Petricevic T; Fernandes Vieira V; Provero P; Fusco C; Cornaz S; Fregni G; Letovanec I; Aguet M; Stamenkovic I
Sci Rep; 2016 Feb; 6():22113. PubMed ID: 26905812
[TBL] [Abstract][Full Text] [Related]
19. Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma.
Brien GL; Remillard D; Shi J; Hemming ML; Chabon J; Wynne K; Dillon ET; Cagney G; Van Mierlo G; Baltissen MP; Vermeulen M; Qi J; Fröhling S; Gray NS; Bradner JE; Vakoc CR; Armstrong SA
Elife; 2018 Nov; 7():. PubMed ID: 30431433
[TBL] [Abstract][Full Text] [Related]
20. Loss of SS18-SSX1 inhibits viability and induces apoptosis in synovial sarcoma.
Carmody Soni EE; Schlottman S; Erkizan HV; Uren A; Toretsky JA
Clin Orthop Relat Res; 2014 Mar; 472(3):874-82. PubMed ID: 23716114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
